Exploring Novel Management Options for Alopecia Areata
March 2026
in “
The American Journal of Managed Care
”
Studysummary The authors concluded that FDA-approved JAK inhibitors, shown to be safe and effective in phase 3 trials, are promising treatment options for severe alopecia areata.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document explores novel management options for alopecia areata (AA), emphasizing the role of JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—in treatment. These inhibitors have shown efficacy in reducing scalp hair loss in clinical trials involving thousands of patients, with significant improvements in SALT scores. However, they also pose risks of serious adverse events, requiring careful risk-benefit assessments. The document underscores challenges such as high treatment costs, insurance issues, and lack of disease awareness, which exacerbate the psychosocial impact of AA. It calls for managed care professionals to improve access to therapies and provide psychosocial support to enhance patient outcomes.
